XIENCE XPEDITION 1074250-23Recalls & reported problems
Abbott Vascular Inc. · XIENCE Xpedition Everolimus Eluting Coronary Stent System 2.50 mm x 23 mm / Rapid-Exchange · Class 3 · Implant
All models of XIENCE XPEDITION (41)
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 2
- Deaths reported
- 0
- Injuries reported
- 2
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 08717648162152), received between Oct 17, 2016 and Feb 2, 2023 — classified as 2 injuries.
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Most reported problems
Device problems
- Adverse Event Without Identified Device or Use Problem2
Patient problems
- Stenosis2
- Angina1
Recent adverse event reports
The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.
InjuryFeb 2, 2023Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
PROC-124212/CN-150010: CAPTURING THE 2.5X23MM XIENCE XPEDITION STENT: IT WAS REPORTED THAT ON 11/8/2021, A 2.5X23MM XIENCE XPEDITION STENT WAS SUCCESSFULLY IMPLANTED IN THE LEFT CIRCUMFLEX ARTERY (LCX). ON (B)(6) 2022, THE PATIENT WAS RE-HOSPITALIZED. MEDICATIONS WERE CHANGED AND REVASCULARIZATION WAS PERFORMED IN THE LCX USING A DRUG COATED BALLOON (DCB). THERE WAS NO ADVERSE PATIENT SEQUELA. NO ADDITIONAL INFORMATION WAS PROVIDED.
Patient problems: Angina; Stenosis
MAUDE report 16285103 ↗InjuryOct 17, 2016Adverse Event Without Identified Device or Use Problem
IT WAS REPORTED THAT ON (B)(6) 2013, A 2.5X18MM ABSORB BIORESORBABLE VASCULAR SCAFFOLD (BVS) WAS SUCCESSFULLY IMPLANTED IN THE DISTAL LEFT ANTERIOR DESCENDING (LAD) CORONARY ARTERY LESION AND A 2.5X23MM XIENCE XPEDITION STENT WAS SUCCESSFULLY IMPLANTED IN THE OBTUSE MARGINAL (OM) CORONARY ARTERY LESION. DURING A FOLLOW-UP, ON (B)(6) 2016, RESTENOSIS WAS NOTED IN THE DISTAL LAD AND OM. MEDICATION WAS PROVIDED. ON (B)(6) 2016 THE PATIENT WAS HOSPITALIZED AND ANOTHER PERCUTANEOUS INTERVENTION, PLACING A STENT IN THE 90% RESTENOSED DISTAL LAD SCAFFOLD AND A STENT IN THE OBTUSE MARGINAL, 90% RESTENOSED STENT. THE EVENT RESOLVED WITHOUT SEQUELA. ON (B)(6) 2016, THE PATIENT WAS DISCHARGED FROM THE HOSPITAL. THERE WAS NO ADDITIONAL INFORMATION PROVIDED.
Patient problems: Stenosis
MAUDE report 6034154 ↗
Other Coronary drug-eluting stent devices
- SYNERGY™ H7493926038300Boston Scientific Corporation · Coronary drug-eluting stent8 deaths124 reports
- SYNERGY™ H7493926016300Boston Scientific Corporation · Coronary drug-eluting stent7 deaths106 reports
- SYNERGY™ H7493926020300Boston Scientific Corporation · Coronary drug-eluting stent9 deaths90 reports
- SYNERGY™ H7493926016250Boston Scientific Corporation · Coronary drug-eluting stent6 deaths82 reports
- XIENCE Sierra™ 1550350-33Abbott Vascular Inc. · Coronary drug-eluting stent1 recall32 reports
- Resolute Onyx™ RONYX30022UXMedtronic, Inc. · Coronary drug-eluting stent6 deaths76 reports
- SYNERGY™ H7493926024300Boston Scientific Corporation · Coronary drug-eluting stent3 deaths75 reports
- Resolute Onyx™ RONYX30015UXMedtronic, Inc. · Coronary drug-eluting stent3 deaths73 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page